AKEBIA THERAPEUTICS, INC. STOCK OPTION AGREEMENT FOR OFFICERSStock Option Agreement • August 28th, 2023 • Akebia Therapeutics, Inc. • Pharmaceutical preparations
Akebia Therapeutics, Inc. (the “Company”) hereby grants the following stock option pursuant to its 2023 Stock Incentive Plan (the “Plan”). The terms and conditions attached hereto are also a part hereof.
AKEBIA THERAPEUTICS, INC. OFFICER INDUCEMENT AWARD STOCK OPTION AGREEMENTOfficer Inducement Award Stock Option Agreement • August 28th, 2023 • Akebia Therapeutics, Inc. • Pharmaceutical preparations
Akebia Therapeutics, Inc. (the “Company”) hereby grants the following inducement non-statutory stock option award. The terms and conditions attached hereto are also a part hereof.
AKEBIA THERAPEUTICS, INC. RESTRICTED STOCK UNIT AGREEMENT FOR OFFICERSRestricted Stock Unit Agreement • August 28th, 2023 • Akebia Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This grant of RSUs satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. License Agreement By...License Agreement • August 28th, 2023 • Akebia Therapeutics, Inc. • Pharmaceutical preparations • England and Wales
This License Agreement (this “Agreement”) is made and entered into as of May 24, 2023 (the “Effective Date”) between Akebia Therapeutics, Inc., a company organized and existing under the laws of the State of Delaware, United States of America with its principal offices at 245 First Street, Cambridge, MA 02142 (“Akebia”), and MEDICE Arzneimittel Pütter GmbH & Co. KG, (“Licensee”), a limited partnership organized under the laws of Germany, with corporate domicile at Kuhloweg 37, 58638 Iserlohn, Germany, registered at local court Iserlohn, HRA 1037, represented by its general partner Medice Verwaltungs-GmbH, a private liability company with identical corporate domicile, registered at local court Iserlohn, HRB 200, represented by Dr. Richard Ammer.
AKEBIA THERAPEUTICS, INC. RESTRICTED STOCK UNIT AGREEMENT FOR NON-EMPLOYEE DIRECTORSRestricted Stock Unit Agreement • August 28th, 2023 • Akebia Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This grant of RSUs satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.
PACKAGING VALIDATION TRANSFER AGREEMENTPackaging Validation Transfer Agreement • August 28th, 2023 • Akebia Therapeutics, Inc. • Pharmaceutical preparations • New York
This PACKAGING VALIDATION TRANSFER AGREEMENT (this “Agreement”) is entered into as of April 20, 2023 (the “Effective Date”), by and between Akebia Therapeutics, Inc., a company organized and existing under the laws of the State of Delaware, United States of America with its principal offices at 245 First Street, Cambridge, MA 02142 (“Akebia”), and Otsuka Pharmaceutical Co. Ltd., a company organized and existing under the laws of Japan, having a registered office located at 2-9, Kanda Tsukasamachi, Chiyoda-ku, Tokyo 101-8535, Japan (“Otsuka”). Each of Akebia and Otsuka are sometimes referred to herein individually as a “Party” and together as the “Parties.”
Akebia Letterhead] June 9, 2023 BY EMAIL David Spellman Dear Dave:Separation Agreement • August 28th, 2023 • Akebia Therapeutics, Inc. • Pharmaceutical preparations
This letter agreement (“Agreement”) confirms the terms of your separation from Akebia Therapeutics, Inc. (“Akebia” or the “Company”).1 Unless you rescind your assent as set forth in Section 5(viii) below, this Agreement shall be effective, final and binding upon the expiration of any applicable Revocation Period set forth in Section 5(viii) (the “Effective Date”).
THIRD AMENDMENT TO LOAN AGREEMENTLoan Agreement • August 28th, 2023 • Akebia Therapeutics, Inc. • Pharmaceutical preparations • New York
This THIRD AMENDMENT TO LOAN AGREEMENT (this “Amendment”), dated and effective as of June 30, 2023 (the “Third Amendment Effective Date”), by and among AKEBIA THERAPEUTICS, INC., a Delaware corporation (as “Borrower”), BIOPHARMA CREDIT PLC, a public limited company incorporated under the laws of England and Wales (as the “Collateral Agent”), BPCR LIMITED PARTNERSHIP, a limited partnership established under the laws of England and Wales (as a “Lender”), and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP, a Cayman Islands exempted limited partnership (as a “Lender”).
